
Please try another search
Pharma ETFs have seen solid trading on Feb 28 as positive drug data and events in the cannabis industry were cheered by investors. Despite the ongoing controversy related to high drug prices, fundamentals appear to be strong for the space. The merger and acquisition backdrop has also been solid in the industry (read: Bristol-Myers to Acquire Celgene (NASDAQ:CELG): Healthcare ETFs in Focus).
Arcadia Eyes Cannabis Industry
Arcadia Biosciences Inc. (NASDAQ:RKDA) — which normally develops food ingredients from wheat and soybeans — saw its shares jump 49% on Feb 28 after it announced plans to foray into the hot hemp or cannabis industry (read: Top ETF Stories of February).
Congress-legalized hemp products, including most CBD, in December in the 2018 Farm Bill. This change has paved the way for the formation of Arcadia Specialty Genomics, which now seeks to tap the rising demand in the hot marijuana space.
Horizon Pharma’s Positive Trial of Eye Disease Treatment
Horizon Pharma Public Limited Company (NASDAQ:HZNP) saw around a 33% jump on Feb 28 as it announced positive results in a late-stage trial of a treatment for active thyroid eye disease, or TED, per the source. The trial successfully met the secondary endpoints and realized a consistent safety profile with the phase 2 study. The company is looking to submit a biologics license application to the FDA in mid-2019.
TG Therapeutics Comes Up With Positive Umbralisib Data
This Zacks Rank #1 (Strong Buy) biopharmaceutical company (NASDAQ:TGTX) saw its shares jump 31% on Feb 28, thanks to positive results from a Phase 2b clinical trial, UNITY-NHL, evaluating umbralisib in patients with treatment-resistant non-Hodgkin lymphoma (NHL). Preliminary data will be presented at AACR on Apr 1.
Decent Earnings Season
The space has been coming up with decent corporate results. Per the Earnings Trends issued on Feb 20, 2019, earnings growth in the fourth quarter is likely to be 10.2% on 7.9% higher revenues (read: A Look at Pharma ETFs Post Q4 Results).
ETFs in Focus
Below we highlight a few top-ranked ETFs that added more than 1% on Feb 28 and have been trading around a one-month high.
First Trust Nasdaq Pharmaceuticals ETF FTXH — Up 2.1% on Feb 28
SPDR S&P Pharmaceuticals (NYSE:XPH) ETF (HN:XPH) — Up 2.0% on Feb 28
iShares US Pharmaceuticals ETF IHE — Up 1.3% on Feb 28
Invesco Dynamic Pharmaceuticals ETF (WA:PJP) — Up 1.2% on Feb 28
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
As markets try to look through the blizzard of policy changes flowing out of Washington, the crowd has shifted its preferences considerably in recent weeks based on a sector lens....
Nvidia’s muted reaction keeps tech on edge, with chipmakers in focus. Nasdaq’s 20980-21000 support holds—for now. A break could mean trouble. With Nvidia done, GDP today and...
Here’s where I see stocks now: Yes, we’ve got some legitimate concerns as some economic warning signs appear—and run up against the tech-driven optimism that’s powered stocks to...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.